Trinity St James’s Cancer Institute names co-directors Trinity St James’s Cancer Institute (TSJCI), jointly operated by Trinity and St James’s Hospital, has named Professor Maeve Lowery and Professor John Kennedy as joint directors of the institute P rofessor Maeve Lowery is Professor of Translational Cancer Medicine at Trinity and Consultant Medical Oncologist at St James’s Hospital. She is a clinical and translational researcher specialising in gastrointestinal oncology who returned to Ireland in 2017 from Memorial Sloan Kettering Cancer Center, to help to develop TSJCI. Professor John Kennedy is a Trinity alumnus and former consultant medical oncologist in St James’s Hospital and St Luke’s Hospital specialising in breast cancer. In 2016 he became Clinical Professor of Oncology at Trinity. He chaired the Cancer Strategy Steering Group that developed Ireland’s National Cancer Strategy 2017-2026. Professors Lowery and Kennedy will take over from Professor Paul Browne, former Head of the School of Medicine at Trinity, who led TSJCI to international accreditation last year. The appointments mark a further step in the plans of TSJCI to harness its world-class academic and clinical expertise to enhance the development of new treatments, diagnostics and prevention strategies in a dedicated cancer institute. Benchmarked against the highest international standards and aligned with the strategic priorities of the National Cancer Strategy, TSJCI is a unique opportunity to transform cancer care in Ireland. Evidence shows that the best outcomes for patients are achieved in centres of excellence, where evidence-based cancer care is developed by combining scientific and technological advances. World-class research supports innovation, and the development of innovative cancer therapies through the mechanism of cancer clinical trials will improve patient experiences and outcomes. TSJCI is the only Cancer Centre in Ireland accredited by the Organisation of European Cancer Institutes. The long-term ambition of the Institute is to become a fully Comprehensive Cancer Centre with outstanding treatment for patients, wide-ranging educational programmes and cutting-edge research in areas such as cancer molecular diagnostics, genomics and translational immuno-oncology.
Download PDF file